Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

204 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A pharmacodynamic model of Aurora kinase inhibitors in the spindle assembly checkpoint.
Mistry HB, MacCallum DE, Jackson RC, Chaplain MA, Davidson FA. Mistry HB, et al. Front Biosci (Landmark Ed). 2010 Jan 1;15:249-58. doi: 10.2741/3619. Front Biosci (Landmark Ed). 2010. PMID: 20036819
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.
Wang S, Griffiths G, Midgley CA, Barnett AL, Cooper M, Grabarek J, Ingram L, Jackson W, Kontopidis G, McClue SJ, McInnes C, McLachlan J, Meades C, Mezna M, Stuart I, Thomas MP, Zheleva DI, Lane DP, Jackson RC, Glover DM, Blake DG, Fischer PM. Wang S, et al. Chem Biol. 2010 Oct 29;17(10):1111-21. doi: 10.1016/j.chembiol.2010.07.016. Chem Biol. 2010. PMID: 21035734
An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor.
Kamei H, Jackson RC, Zheleva D, Davidson FA. Kamei H, et al. J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):407-34. doi: 10.1007/s10928-010-9166-0. Epub 2010 Aug 8. J Pharmacokinet Pharmacodyn. 2010. PMID: 20694801
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.
Wang S, Midgley CA, Scaƫrou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G, McClue SJ, McInnes C, Meades C, Mezna M, Plater A, Stuart I, Thomas MP, Wood G, Clarke RG, Blake DG, Zheleva DI, Lane DP, Jackson RC, Glover DM, Fischer PM. Wang S, et al. J Med Chem. 2010 Jun 10;53(11):4367-78. doi: 10.1021/jm901913s. J Med Chem. 2010. PMID: 20462263
Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase.
Mistry HB, MacCallum DE, Jackson RC, Chaplain MA, Davidson FA. Mistry HB, et al. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20215-20. doi: 10.1073/pnas.0810706106. Epub 2008 Dec 17. Proc Natl Acad Sci U S A. 2008. PMID: 19091947 Free PMC article.
A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.
Jackson RC, Radivoyevitch T. Jackson RC, et al. Cancer Chemother Pharmacol. 2014 Oct;74(4):765-76. doi: 10.1007/s00280-014-2556-z. Epub 2014 Aug 9. Cancer Chemother Pharmacol. 2014. PMID: 25107570
Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy.
Jackson RC, Di Veroli GY, Koh SB, Goldlust I, Richards FM, Jodrell DI. Jackson RC, et al. PLoS Comput Biol. 2017 May 3;13(5):e1005529. doi: 10.1371/journal.pcbi.1005529. eCollection 2017 May. PLoS Comput Biol. 2017. PMID: 28467408 Free PMC article.
Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development.
Chassagnole C, Jackson RC, Hussain N, Bashir L, Derow C, Savin J, Fell DA. Chassagnole C, et al. Biosystems. 2006 Feb-Mar;83(2-3):91-7. doi: 10.1016/j.biosystems.2005.04.007. Epub 2005 Oct 19. Biosystems. 2006. PMID: 16236428
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW. Allen MD, et al. Cancer Res. 2014 Feb 1;74(3):896-907. doi: 10.1158/0008-5472.CAN-13-1702. Epub 2013 Nov 27. Cancer Res. 2014. PMID: 24285724
The spindle assembly checkpoint and speciation.
Jackson RC, Mistry HB. Jackson RC, et al. PeerJ. 2020 May 11;8:e9073. doi: 10.7717/peerj.9073. eCollection 2020. PeerJ. 2020. PMID: 32435535 Free PMC article.
204 results
Jump to page